With new $10.6B fund, Hill­house Cap­i­tal sets the stage for splashy Asia-fo­cused biotech deals

Hav­ing thrown its weight be­hind some of the biggest biotech fi­nanc­ing rounds of the year, Chi­na’s pri­vate eq­ui­ty pow­er­house Hill­house Cap­i­tal has re­loaded with a $10.6 bil­lion fund.

Oth­er than health­care, Hill­house Fund IV will al­so pur­sue op­por­tu­ni­ties in con­sumer, tech­nol­o­gy and ser­vices sec­tors glob­al­ly, though Asia re­mains the key fo­cus. It’s one of the largest pri­vate eq­ui­ty fundrais­ings in 2018, ac­cord­ing to Bloomberg.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.